Wave Life Sciences Ltd (WVE) - Total Assets
Based on the latest financial reports, Wave Life Sciences Ltd (WVE) holds total assets worth $583.54 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See WVE net asset value for net asset value and shareholders' equity analysis.
Wave Life Sciences Ltd - Total Assets Trend (2013–2025)
This chart illustrates how Wave Life Sciences Ltd's total assets have evolved over time, based on quarterly financial data.
Wave Life Sciences Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Wave Life Sciences Ltd's total assets of $583.54 Million consist of 96.3% current assets and 3.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 94.3% |
| Accounts Receivable | $1.28 Million | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Wave Life Sciences Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Wave Life Sciences Ltd (WVE) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Wave Life Sciences Ltd's current assets represent 96.3% of total assets in 2025, an increase from 33.5% in 2013.
- Cash Position: Cash and equivalents constituted 94.3% of total assets in 2025, up from 18.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Wave Life Sciences Ltd Competitors by Total Assets
Key competitors of Wave Life Sciences Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
|
Jade Biosciences, Inc.
NASDAQ:JBIO
|
USA | $319.43 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Wave Life Sciences Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.26 | 2.95 | 3.41 |
| Quick Ratio | 11.26 | 2.95 | 3.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $511.44 Million | $170.61 Million | $112.71 Million |
Wave Life Sciences Ltd - Advanced Valuation Insights
This section examines the relationship between Wave Life Sciences Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.81 |
| Latest Market Cap to Assets Ratio | 1.92 |
| Asset Growth Rate (YoY) | 81.3% |
| Total Assets | $638.50 Million |
| Market Capitalization | $1.23 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Wave Life Sciences Ltd's assets above their book value (1.92x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Wave Life Sciences Ltd's assets grew by 81.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Wave Life Sciences Ltd (2013–2025)
The table below shows the annual total assets of Wave Life Sciences Ltd from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $638.50 Million | +81.29% |
| 2024-12-31 | $352.21 Million | +28.10% |
| 2023-12-31 | $274.95 Million | +87.82% |
| 2022-12-31 | $146.39 Million | -29.28% |
| 2021-12-31 | $207.01 Million | -25.87% |
| 2020-12-31 | $279.24 Million | -1.76% |
| 2019-12-31 | $284.25 Million | -3.95% |
| 2018-12-31 | $295.94 Million | +62.74% |
| 2017-12-31 | $181.84 Million | +10.33% |
| 2016-12-31 | $164.81 Million | -0.37% |
| 2015-12-31 | $165.42 Million | +5530.50% |
| 2014-12-31 | $2.94 Million | +26.47% |
| 2013-12-31 | $2.32 Million | -- |
About Wave Life Sciences Ltd
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent diso… Read more